ClinicalTrials.gg
CompletedNCT00122304Updated Feb 21, 2007

Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab

A Phase 3 interventional study of eculizumab in Hemoglobinuria, Paroxysmal, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 48 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-02-21.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
85
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal — none open to participants now, none under way, none of them phase 3. eculizumab · Hemoglobinuria, Paroxysmal.

Enrollment
3rd of 18
85 · median 37
Started
2004
with 2 others
Phase 3
14 of 18
none open now
Registered
3rd of 18
by date
Lead sponsor
8 of 18
Alexion Pharmaceuticals, Inc.

Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, this one is the 3rd largest by enrollment, is one of 3 that started in 2004, is one of 14 in phase 3, and was the 3rd registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

None of the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal is open now. The open studies under Hemoglobinuria, Paroxysmal, anywhere →

About eculizumab

eculizumab: first FDA approval 2007 (SOLIRIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal as a file.
02

Study summary

The primary objective is to evaluate the safety of eculizumab in patients with transfusion-dependent hemolytic PNH

03

Conditions studied

  • Hemoglobinuria, Paroxysmal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PNH > 6 months
  • Type III PNH red blood cell (RBC) clone by flow cytometry >10%
  • At least one transfusion in the past 2 years but no more than 3 transfusions in the past 12 months; or personal beliefs that preclude the use of transfusion with severe hemolytic PNH
  • Lactate dehydrogenase (LDH) >1.5 x
  • Must avoid conception
  • Willing and able to give written

Exclusion criteria

Exclusion Criteria:

  • count of \<30,000/mm3
  • \<500/ul
  • Active bacterial infection
  • Hereditary complement deficiency
  • History of bone marrow transplantation
  • Participation in any other drug trial or exposure to other investigational agent, device or procedure within 30 days
  • Pregnant, breast-feeding, or intending to conceive
  • History of meningococcal disease
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
85 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Acceptable safety (adverse events [AEs], labs, electrocardiograms [ECGs], vital signs)

  2. Primary surrogate of efficacy endpoint is hemolysis measured by LDH area under the curve.

Secondary outcomes

  1. Hemolysis measured by the change of LDH from baseline;

  2. Quality of Life

07

Study locations

48 sites
  • Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Stanford University Medical Center, Division of Hematology
    Stanford, California 94305, United States
  • Hartford Hospital, Cancer Clinical Research Office
    Hartford, Connecticut 06102, United States
  • Cleveland Clinic Florida, Dept. of Clinical Research
    Weston, Florida 33331, United States
  • Indiana University Cancer Pavilion
    Indianapolis, Indiana 46202, United States
  • Johns Hopkins University Medical Center
    Baltimore, Maryland 21205, United States
  • National Heart, Lung, and Blood Institute, National Institutes of Health
    Bethesda, Maryland 20892, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Mayo Clinic, Division of Hematology
    Rochester, Minnesota 55905, United States
  • Washington University Medical Center, Department of Internal Medicine/Division of Hematology
    St. Louis, Missouri 63110, United States
  • Cooper University Hospital, Cooper Cancer Institute
    Voorhees, New Jersey 08043, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • NYU Clinical Cancer Center
    New York, New York 10016, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10017, United States
  • Duke University Medical Center, Division Cell Therapy, Heme Malignancies Program
    Durham, North Carolina 27710, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • OHSU Center for Hematologic Malignancies
    Portland, Oregon 97239, United States
  • Presbyterian Medical Center, PENN Comprehensive Hemophilia & Thrombosis Program
    Philadelphia, Pennsylvania 19104, United States
  • University of Utah, Hematology-BMT Department
    Salt Lake City, Utah 84132, United States
  • Royal North Shore Hospital, Haematology Department
    St. Leonard, New South Wales 2065, Australia
  • Princess Alexandra Hospital, Oncology Haematology Radiation Department
    Woolloongabba, Queensland 4102, Australia
  • The Queen Elizabeth Hospital, Haematology/Oncology Department
    Woodville South, South Australia 5011, Australia
  • The Royal Perth Hospital, Dept. of Haematology/Level 2
    Perth, Western Australia 6000, Australia
  • Royal Melbourne Hospital, Dept. of Clinical Haematology & Medical Oncology
    Parkville, 3050, Australia
  • Ucl St. Luc, Hematology Department
    Brussels, 1200, Belgium
  • University of Alberta, Cross Cancer Institute
    Edmonton, Alberta T6G 2B7, Canada
  • London Regional Cancer Centre, Clinical Research Unit Room C3080
    London, Ontario N6A 4L6, Canada
  • Hopital Saint-Louis, Centre d'investigation Clinique
    Paris, Cedex 10 75475, France
  • Universitatsklinikum Essen, Zentrum fur Innere Medizin
    Essen, D-45147, Germany
  • Medizinische Hochschule Hannover, Abt. Hamatologie/Onkologie, Zentrum fur Innere Medizin
    Hannover, D-30625, Germany
  • Universitatskliniken des Saarlandes, Innere Medizin 1
    Homburg/Saar, D-66421, Germany
  • Institut fur Klinische Transfusionmedizin und Immungenetik, Abtlg. Transfusionmedizin des Univer. Ulm
    Ulm, D-89081, Germany
  • St. James Hospital, Haematology Dept., Cancer Clinical Trial Office
    Dublin, 8, Ireland
  • Azienda Ospedaliera Universitaria Careggi, Dipartimento di area critica medico-chirurgica
    Firenze, 50139, Italy
  • Ospedale San Martino, Dept. of Hematology
    Genova, I-16132, Italy
  • Ospedale Maggiore di Milano, Divisione di Ematologia
    Milano, 35-20122, Italy
  • Universita degli Studi di Napoli, Divisione di Ematologia, Azienda Universitar Policlinico
    Napoli, 5-80131, Italy
  • Ospedale San Bortolo, Divisione di Ematologia
    Vicenza, 37-36100, Italy
  • UMC St. Radboud, Department of Hematology
    Nijmegen, 6525 GA, Netherlands
  • Hospital Clinic i Provincial, Servicio de Hematologia
    Barcelona, 08036, Spain
  • Hospital Universitario Germans Trias I Pujol, Servicio de Hematologia
    Barcelona, 08916, Spain
  • Hospital De La Paz, Servicio de Hematologia
    Madrid, 28046, Spain
  • Stockholm South Hospital, Division of Hematology
    Stockholm, 118-83, Sweden
  • University Hospital, Dept. of Haematology
    Uppsala, SE-751, Sweden
  • Kantonsspital Basel, Abteilung fuer Haematologie
    Basel, CH-4031, Switzerland
  • Royal Cornwall Hospital
    Truro, Cornwall TR1 3LJ, United Kingdom
  • Leeds General Infirmary, D Floor Brotherton Wing
    Leeds, LS1 3EX, United Kingdom
  • St. Georges Hospital, Department of Haematology
    London, 17 OQT, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2005
First posted
Jul 22, 2005
Start
Dec 2004
Completion
Nov 2006
Last update
Feb 21, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Feb 21, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00122304
First posted
Jul 22, 2005
Start date
Dec 2004
Completion
Nov 2006
Last update
Feb 21, 2007
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion